COVID-19 Dual-Antibody Therapies Found Effective Against SARS-CoV-2 Variants in Animal Study
By HospiMedica International staff writers Posted on 23 Jun 2021 |

Image: COVID-19 Dual-Antibody Therapies Found Effective Against SARS-CoV-2 Variants in Animal Study (Photo courtesy of Matt Miller)
A study to assess how well antibody-based drugs for COVID-19 perform against a range of virus variants has found that dual-antibody therapies appear to prevent the emergence of drug resistance.
New research at Washington University School of Medicine in St. Louis (St. Louis, MO, USA) suggests that many, but not all, therapies made from combinations of two antibodies are effective against a wide range of variants of the virus. Further, combination therapies appear to prevent the emergence of drug resistance. The study, in mice and hamsters, tested all single and combination antibody-based therapies authorized for emergency use by the Food and Drug Administration (FDA), or that are being evaluated in late-stage clinical trials, against a panel of emerging international and U.S. variants of SARS-CoV-2, the virus that causes COVID-19. The findings suggest that COVID-19 drugs made of two antibodies often retain potency as a therapy against variants even when in vitro studies - experiments conducted in a dish - indicate that one of the two antibodies has lost some or all ability to neutralize the variant.
So-called monoclonal antibodies mimic those generated by the body to fight off the virus that causes COVID-19. Administration of antibody therapies bypasses the body’s slower and sometimes less effective process of making its own antibodies. At the time this study began, there were two dual-antibody combination therapies and a single antibody therapy authorized by the FDA for emergency use. The FDA withdrew authorization for the single antibody therapy, bamlanivimab, in April on the grounds that it was not effective against the variants circulating at that time. In May, the FDA authorized the single antibody sotrovimab as a treatment for COVID-19.
The researchers tested the antibodies against a panel of virus variants containing key mutations in their spike genes. The SARS-CoV-2 virus uses spike protein to invade cells. All monoclonal antibody-based COVID-19 therapies work by interfering with the interaction between spike protein and cells. In all, the researchers evaluated antibodies corresponding to the FDA-authorized ones made by Eli Lilly and Co., Regeneron and Vir Biotechnology/GlaxoSmithKline, as well as the antibodies currently under development by AbbVie, Vir and AstraZeneca that are in clinical trials.
The panel included mutations found in three of the four variants that have been designated “variants of concern” by the World Health Organization - Alpha (first identified in the United Kingdom), Beta (South Africa) and Gamma (Brazil) - as well as an emerging variant from India similar to the Delta variant of concern. They also tested variants from New York and California. The researchers used a mix of virus samples originally obtained from people with COVID-19 and laboratory strains genetically engineered to contain key mutations. The researchers evaluated the antibodies in hamsters and two strains of mice. The researchers first gave the animals antibodies - singly or in the same combinations in which they are given to treat patients - a day before infecting them with one of the virus variants. The researchers monitored the animals’ weight for six days and then measured the amount of virus in their noses, lungs and other parts of the body.
Although some single antibodies showed reduced or no ability to neutralize virus variants in a dish, low doses of most of the antibody combinations protected against disease caused by many of the variants. The researchers sequenced viral samples from the animals and found no evidence of drug resistance in viruses from any of the animals that had been treated with combination therapies. Since antibody-based COVID-19 therapies primarily are used to treat people who already are infected, the researchers also evaluated how well the antibody combinations performed when given after infection with the Beta variant. The Beta variant was chosen because it has been shown to be most likely to escape neutralization in laboratory-based experiments and has the most resistance to COVID-19 vaccines. The antibody cocktails corresponding to those from AstraZeneca, Regeneron and Vir were all effective at reducing disease caused by the Gamma variant; the one from AbbVie only was partially protective, and the one from Lilly showed no efficacy at all.
“When we looked in animals, there were some surprises. Some of the combinations performed better than we thought they would, based on in vitro data,” said senior author Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine. “And there was no drug resistance to combinations whatsoever, across all of the different variants. We’re going to have to continue to monitor the effectiveness of antibody therapy as more variants arise, but combination therapy is likely needed for treating infections with this virus as more variants emerge.”
“Dual therapy seemed to prevent the emergence of resistant viruses,” said co-author Jacco Boon, PhD, an associate professor of medicine, of molecular microbiology and of pathology & immunology. “Resistance arose with some of the monotherapies, but never with combination therapy.”
Related Links:
Washington University School of Medicine in St. Louis
New research at Washington University School of Medicine in St. Louis (St. Louis, MO, USA) suggests that many, but not all, therapies made from combinations of two antibodies are effective against a wide range of variants of the virus. Further, combination therapies appear to prevent the emergence of drug resistance. The study, in mice and hamsters, tested all single and combination antibody-based therapies authorized for emergency use by the Food and Drug Administration (FDA), or that are being evaluated in late-stage clinical trials, against a panel of emerging international and U.S. variants of SARS-CoV-2, the virus that causes COVID-19. The findings suggest that COVID-19 drugs made of two antibodies often retain potency as a therapy against variants even when in vitro studies - experiments conducted in a dish - indicate that one of the two antibodies has lost some or all ability to neutralize the variant.
So-called monoclonal antibodies mimic those generated by the body to fight off the virus that causes COVID-19. Administration of antibody therapies bypasses the body’s slower and sometimes less effective process of making its own antibodies. At the time this study began, there were two dual-antibody combination therapies and a single antibody therapy authorized by the FDA for emergency use. The FDA withdrew authorization for the single antibody therapy, bamlanivimab, in April on the grounds that it was not effective against the variants circulating at that time. In May, the FDA authorized the single antibody sotrovimab as a treatment for COVID-19.
The researchers tested the antibodies against a panel of virus variants containing key mutations in their spike genes. The SARS-CoV-2 virus uses spike protein to invade cells. All monoclonal antibody-based COVID-19 therapies work by interfering with the interaction between spike protein and cells. In all, the researchers evaluated antibodies corresponding to the FDA-authorized ones made by Eli Lilly and Co., Regeneron and Vir Biotechnology/GlaxoSmithKline, as well as the antibodies currently under development by AbbVie, Vir and AstraZeneca that are in clinical trials.
The panel included mutations found in three of the four variants that have been designated “variants of concern” by the World Health Organization - Alpha (first identified in the United Kingdom), Beta (South Africa) and Gamma (Brazil) - as well as an emerging variant from India similar to the Delta variant of concern. They also tested variants from New York and California. The researchers used a mix of virus samples originally obtained from people with COVID-19 and laboratory strains genetically engineered to contain key mutations. The researchers evaluated the antibodies in hamsters and two strains of mice. The researchers first gave the animals antibodies - singly or in the same combinations in which they are given to treat patients - a day before infecting them with one of the virus variants. The researchers monitored the animals’ weight for six days and then measured the amount of virus in their noses, lungs and other parts of the body.
Although some single antibodies showed reduced or no ability to neutralize virus variants in a dish, low doses of most of the antibody combinations protected against disease caused by many of the variants. The researchers sequenced viral samples from the animals and found no evidence of drug resistance in viruses from any of the animals that had been treated with combination therapies. Since antibody-based COVID-19 therapies primarily are used to treat people who already are infected, the researchers also evaluated how well the antibody combinations performed when given after infection with the Beta variant. The Beta variant was chosen because it has been shown to be most likely to escape neutralization in laboratory-based experiments and has the most resistance to COVID-19 vaccines. The antibody cocktails corresponding to those from AstraZeneca, Regeneron and Vir were all effective at reducing disease caused by the Gamma variant; the one from AbbVie only was partially protective, and the one from Lilly showed no efficacy at all.
“When we looked in animals, there were some surprises. Some of the combinations performed better than we thought they would, based on in vitro data,” said senior author Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine. “And there was no drug resistance to combinations whatsoever, across all of the different variants. We’re going to have to continue to monitor the effectiveness of antibody therapy as more variants arise, but combination therapy is likely needed for treating infections with this virus as more variants emerge.”
“Dual therapy seemed to prevent the emergence of resistant viruses,” said co-author Jacco Boon, PhD, an associate professor of medicine, of molecular microbiology and of pathology & immunology. “Resistance arose with some of the monotherapies, but never with combination therapy.”
Related Links:
Washington University School of Medicine in St. Louis
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
AI-Powered Algorithm to Revolutionize Detection of Atrial Fibrillation
Atrial fibrillation (AFib), a condition characterized by an irregular and often rapid heart rate, is linked to increased risks of stroke and heart failure. This is because the irregular heartbeat in AFib... Read more
AI Diagnostic Tool Accurately Detects Valvular Disorders Often Missed by Doctors
Doctors generally use stethoscopes to listen for the characteristic lub-dub sounds made by heart valves opening and closing. They also listen for less prominent sounds that indicate problems with these valves.... Read moreCritical Care
view channel
Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
Atrial fibrillation, the most common type of cardiac arrhythmia worldwide, affected approximately 59 million people in 2019. Characterized by an irregular and often rapid heart rate, atrial fibrillation... Read more
Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
The peripheral nervous system (PNS) serves as the communication network that links the brain and spinal cord to every other part of the body. It consists of two parts: the somatic nervous system, which... Read moreSurgical Techniques
view channel
Hydrogel-Based Miniaturized Electric Generators to Power Biomedical Devices
The development of engineered devices that can harvest and convert the mechanical motion of the human body into electricity is essential for powering bioelectronic devices. This mechanoelectrical energy... Read more
Wearable Technology Monitors and Analyzes Surgeons' Posture during Long Surgical Procedures
The physical strain associated with the static postures maintained by neurosurgeons during long operations can lead to fatigue and musculoskeletal problems. An objective assessment of surgical ergonomics... Read more.jpg)
Custom 3D-Printed Orthopedic Implants Transform Joint Replacement Surgery
The evolving field of 3D printing is revolutionizing orthopedics, especially for individuals requiring joint replacement surgeries where traditional implants fail to provide a solution. Although most people... Read more
Cutting-Edge Imaging Platform Detects Residual Breast Cancer Missed During Lumpectomy Surgery
Breast cancer is becoming increasingly common, with statistics indicating that 1 in 8 women will develop the disease in their lifetime. Lumpectomy remains the predominant surgical intervention for treating... Read morePatient Care
view channel
Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization
An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more
Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
A groundbreaking innovation enables hospitals to significantly improve instrument processing time and throughput in operating rooms (ORs) and sterile processing departments. Turbett Surgical, Inc.... Read more
Next Gen ICU Bed to Help Address Complex Critical Care Needs
As the critical care environment becomes increasingly demanding and complex due to evolving hospital needs, there is a pressing requirement for innovations that can facilitate patient recovery.... Read more
Groundbreaking AI-Powered UV-C Disinfection Technology Redefines Infection Control Landscape
Healthcare-associated infection (HCAI) is a widespread complication in healthcare management, posing a significant health risk due to its potential to increase patient morbidity and mortality, prolong... Read moreHealth IT
view channel
Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients
Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more
Strategic Collaboration to Develop and Integrate Generative AI into Healthcare
Top industry experts have underscored the immediate requirement for healthcare systems and hospitals to respond to severe cost and margin pressures. Close to half of U.S. hospitals ended 2022 in the red... Read more
AI-Enabled Operating Rooms Solution Helps Hospitals Maximize Utilization and Unlock Capacity
For healthcare organizations, optimizing operating room (OR) utilization during prime time hours is a complex challenge. Surgeons and clinics face difficulties in finding available slots for booking cases,... Read more
AI Predicts Pancreatic Cancer Three Years before Diagnosis from Patients’ Medical Records
Screening for common cancers like breast, cervix, and prostate cancer relies on relatively simple and highly effective techniques, such as mammograms, Pap smears, and blood tests. These methods have revolutionized... Read morePoint of Care
view channel
Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing
Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Point of Care HIV Test Enables Early Infection Diagnosis for Infants
Early diagnosis and initiation of treatment are crucial for the survival of infants infected with HIV (human immunodeficiency virus). Without treatment, approximately 50% of infants who acquire HIV during... Read more
Whole Blood Rapid Test Aids Assessment of Concussion at Patient's Bedside
In the United States annually, approximately five million individuals seek emergency department care for traumatic brain injuries (TBIs), yet over half of those suspecting a concussion may never get it checked.... Read more
New Generation Glucose Hospital Meter System Ensures Accurate, Interference-Free and Safe Use
A new generation glucose hospital meter system now comes with several features that make hospital glucose testing easier and more secure while continuing to offer accuracy, freedom from interference, and... Read moreBusiness
view channel
Johnson & Johnson Acquires Cardiovascular Medical Device Company Shockwave Medical
Johnson & Johnson (New Brunswick, N.J., USA) and Shockwave Medical (Santa Clara, CA, USA) have entered into a definitive agreement under which Johnson & Johnson will acquire all of Shockwave’s... Read more